US FDA to Review Sarepta ' s Duchenne Gene Therapy for Traditional Approval US FDA to Review Sarepta ' s Duchenne Gene Therapy for Traditional Approval

Sarepta Therapeutics said on Friday that the US FDA would review an application seeking traditional approval for its gene therapy to treat a muscle-wasting disorder by June...Reuters Health Information
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery Source Type: news